Year-long trial by Oxford University researchers carried out in Burkina Faso shows up to 77 percent efficacy.
With close to half a million deaths from malaria in 2019 – most in sub-Saharan Africa – scientists have spent decades working towards a vaccine, and last week, the World Health Organization approved the first.
But, with only 30 to 40 percent efficacy, some are also asking, is it worth it? And, there are other questions about how quickly it can be deployed.
We talk to one Kenyan scientist who grew up in one of the world’s most malaria-ridden regions and hear about how he is helping to stop this dogged and deadly disease.
In this episode:
- Dr Bernhards Ogutu, chief research officer, Kenya Medical Research Institute @KEMRI_Kenya
Connect with The Take: